Delivery Order SPE2DB24D1104-SPE2DB24FXUN6
- Not listed
- This federal contract award, valued at $1,659.48, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4,561,731,832 units of the pharmaceutical drug Ondansetron ODT 4 MG Tablet, a medication used to treat nausea and vomiting. The contract has an ultimate completion date of August 8, 2023 and is a firm fixed-price delivery order. It is not associated with any set-aside requirements, indicating full...
- This federal contract award, worth $4,486.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of ondansetron ODT 4 mg tablets, a medication used to prevent nausea and vomiting. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the...
- This federal contract award, valued at $1,940.22, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ondansetron ODT 4 mg tablets, a medication used to prevent nausea and vomiting, to support military treatment facilities and other federal healthcare programs. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued...
- This federal contract award, valued at $1,438.24, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ondansetron ODT 4 mg Tablets, a medication commonly used to treat nausea and vomiting. The award is part of a larger Indefinite Delivery Contract (IDC) between the DLA and Cencora, Inc., valued at up to $999,999,999.00, which runs through November 2026. This IDC serves as the...
- This federal contract award, valued at $7,006.29, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ondansetron ODT 4 mg tablets, a medication used to prevent nausea and vomiting. This contract is a delivery order that is part of a larger Indefinite Delivery Contract (IDC) between the DLA and Cencora, Inc., valued at up to $999,999,999.00 and running through December 2025. The...
- This federal contract award, worth $12,645.96, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of ondansetron ODT 4 mg tablets, a medication used to treat nausea and vomiting. The contract has a completion date of May 22, 2023 and is a firm fixed-price delivery order with no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $3,139.54, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ondansetron ODT 8 mg tablets, a medication used to prevent nausea and vomiting. This is a firm-fixed-price delivery order with a completion date of May 7, 2024. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award, valued at $7,612.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4563004203 - Ondansetron ODT 4 mg Tablet 30s, a medication used to treat nausea and vomiting. The award is a Firm Fixed Price Delivery Order with a performance period ending on December 6, 2023. The contract was awarded through full and open competition, with no set-aside designation. Amerisourcebergen...
- This federal contract award, valued at $10,582.05, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Ondansetron ODT 4 mg tablets in 30-count packages, which are used to treat nausea and vomiting. The award is a delivery order under an Indefinite Delivery Contract (IDC) between DLA Troop Support Medical and Cencora, Inc., valued at up to $999,999,999.00 and running through December...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $2,282.37, is for the delivery of Ondansetron ODT 4 mg tablets, a medication used to treat nausea and vomiting. This is a delivery order contract with a firm fixed-price pricing type, and the ultimate completion date is December 20, 2023. The contract is not designated with a set-aside...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB24FXUN6Delivery Order
This federal contract award, valued at $6,852.45, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ondansetron ODT 4 mg tablets, a medication used to prevent nausea and vomiting associated with certain medical treatments. The contract is a Firm Fixed Price Delivery Order with a completion date of February 23, 2024. It is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Additionally, Cencora, Inc. (Amerisourcebergen's parent company) holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.9k | 2/22/24 |